Stéphane Boissel

Chief Executive Officer at SparingVision SAS

Stéphane Boissel

Stéphane Boissel

Chief Executive Officer at SparingVision SAS

Overview
Career Highlights

Sangamo Therapeutics, Inc.
Transgene SA
Innate Pharma SA

RelSci Relationships

581

Number of Boards

9

Birthday

1968

Age

53

Relationships
RelSci Relationships are individuals Stéphane Boissel likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chief Executive Officer at TSGH SAS

Relationship likelihood: Strong

Deputy Chief Executive Officer, Director-Research & Development at Transgene SA

Relationship likelihood: Strong

Vice Chairman at Association Lyon Place Financière

Relationship likelihood: Strong

President, Chief Executive Officer & Director at Anagenesis Biotechnologies SAS

Relationship likelihood: Strong

Chief Executive Officer, Co-Founder at Elsalys Biotech SAS

Relationship likelihood: Strong

Vice President, Alliance Management, Project Management & Marketing at Transgene SA

Relationship likelihood: Strong

Vice President, Corporate Development & Medical Affairs at Transgene SA

Relationship likelihood: Strong

Vice President Quality & Deputy Chief Executive Officer at Transgene SA

Relationship likelihood: Strong

Vice President, Finance at Transgene SA

Relationship likelihood: Strong

Director Général, ABL Europe at Advanced Bioscience Laboratories, Inc.

Relationship likelihood: Strong

Paths to Stéphane Boissel
Potential Connections via
Relationship Science
You
Stéphane Boissel
Chief Executive Officer at SparingVision SAS
Education
Class of 2002

UCE’s Office of Investments is responsible for managing the University's investment assets, which includes overseeing the endowment to ensure that it benefits both current and future generations of the University of Chicago. They oversee the broad investment strategy and provide input to the development of the strategic and tactical investment policies of the University & UCMC endowments, pension plans and self-insurance trust assets. Their strategy combines qualitative and quantitative analysis, seeking to achieve superior investment performance on a risk-adjusted basis.

Degree in Finance
Class of 1993

Université Paris-Dauphine is a company that offers teaching and educational services.

Degree in Finance

The University of Lyon, located in Lyon and Saint-Étienne, France, is a center for higher education and research comprising 16 institutions of higher education. The three main universities in this center are: Claude Bernard University Lyon 1, which focuses upon health and science studies and has approximately 27,000 students; Lumière University Lyon 2, which focuses upon the social sciences and has about 30,000 students; Jean Moulin University Lyon 3, which focuses upon the law and humanities with about 20,000 students.[

MBA

The University of Chicago Booth School of Business is a graduate business school located in Chicago, Illinois, at the University of Chicago. Formerly known as the University of Chicago Graduate School of Business, Chicago Booth is the second-oldest business school in the U.S., the first such school to offer an Executive MBA program, and the first to initiate a Ph.D. program in business. The school was renamed in 2008 following a $300 million endowment gift to the school by alumnus David G. Booth. The school has the third-largest endowment of any business school. The school's flagship campus is located in the Hyde Park neighborhood of Chicago on the main campus of the university. The school also maintains additional campuses in London and Asia (originally Singapore, but in July 2013 a move to Hong Kong was announced), as well as in downtown Chicago on the Magnificent Mile. In addition to conducting graduate business programs, the school conducts research in the fields of finance, economics, quantitative marketing research, and accounting. Chicago Booth is currently ranked first in the United States by Bloomberg Businessweek and first globally by the Economist.

Memberships
Member
Prior

France Biotech is a one stop trade and joint actions for Industry Life Sciences it values through collaborative projects.

Career History
Chief Financial Officer, Executive Vice President & Investor Relations Person
2002 - 2010

Innate Pharma SA is a biopharmaceutical company. It focuses on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. Its products include immunotherapy drugs and monoclonal antibodies. The Immunotherapy drugs are designated for cancer and inflammatory diseases. The Monoclonal antibodies targets receptors and pathways controlling the activation of innate immunity cells. The company was founded by Hervé Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié and François Romagné on September 15, 1999 and is headquartered in Marseille, France.

Chief Financial Officer & Executive Vice President
2010 - 2014

Transgene SA is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of immunotherapies for the treatment of cancer and infectious diseases. Its products include TG4001, TG6002, BT-001 and TG4050. The company was founded in December 1979 and is headquartered in Strasbourg, France.

Supervisor
Prior

Transgene Tasly (Tianjin) Biopharmaceutical Co., Ltd. engages in theresearch and development, and manufacture of immunotherapies for the treatment of oncology and infectious diseases. Its business scope includes biopharmaceutical technology development, technology transfer, and related technical advisory services. The company was founded on July 26, 2010 and is headquartered in Tianjin, China.

Boards & Committees
Chairman, Board of Directors
2020 - Current

SparingVision SAS develops therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa. The company was founded by Jose Alain Sahel, Thierry Leveillard and Florence Allouche Ghrenassia and is headquartered in Paris, France.

Member, Management Committee
Current

Transgene SA is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of immunotherapies for the treatment of cancer and infectious diseases. Its products include TG4001, TG6002, BT-001 and TG4050. The company was founded in December 1979 and is headquartered in Strasbourg, France.

Member, Board of Directors
Current

Transgene Tasly (Tianjin) Biopharmaceutical Co., Ltd. engages in theresearch and development, and manufacture of immunotherapies for the treatment of oncology and infectious diseases. Its business scope includes biopharmaceutical technology development, technology transfer, and related technical advisory services. The company was founded on July 26, 2010 and is headquartered in Tianjin, China.

Public Holdings
Restricted data only for RelSci Professional users.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Stéphane Boissel. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Stéphane Boissel's profile does not indicate a business or promotional relationship of any kind between RelSci and Stéphane Boissel.